Novel smoothened antagonists as anti-neoplastic agents for the treatment of osteosarcoma.

Novel smoothened antagonists as anti-neoplastic agents for the treatment of osteosarcoma.

J Cell Physiol. 2017 Dec 07;:

Authors: Bernardini G, Geminiani M, Gambassi S, Orlandini M, Petricci E, Marzocchi B, Laschi M, Taddei M, Manetti F, Santucci A

Abstract
Osteosarcoma (OS) is an ultra-rare highly malignant tumor of the skeletal system affecting mainly children and young adults and it is characterized by an extremely aggressive clinical course. OS patients are currently treated with chemotherapy and complete surgical resection of cancer tissue. However, resistance to chemotherapy and the recurrence of disease, as pulmonary metastasis, remain the two greatest challenges in the management and treatment of this tumour. For these reasons, it is of primary interest to find alternative therapeutic strategies for OS. Dysregulated Hedgehog signalling is involved in the development of various types of cancers including OS. It has also been implicated in tumor/stromal interaction and cancer stem cell biology, and therefore presents a novel therapeutic strategy for cancer treatment. In our work, we tested the activity of five potent Smoothened (SMO) inhibitors, four acylguanidine and one acylthiourea derivatives, against an OS cell line. We found that almost all our compounds were able to inhibit OS cells proliferation and to reduce Gli1 protein levels. Our results also indicated that SMO inhibition in OS cells by such compounds, induces apoptosis with a nanomolar potency. These findings suggest that inactivation of SMO may be a useful approach to the treatment of patients with OS. This article is protected by copyright. All rights reserved.

PMID: 29215700 [PubMed - as supplied by publisher]

http://ift.tt/2BXCa0e